Payment overview · 2025
General Payments
$254,289.03
364 reported records · 3 companies
Healthcare provider profile · identity verified
Robert Gabriel Feldman, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LAGUNA HILLS, CA · NPI 1194805416
Verified facts
What the public records show
CMS Open Payments records show Robert Gabriel Feldman, M.D. received $254,289.03 in general payments during 2025 across 364 reported records.
GlaxoSmithKline, LLC. accounted for 48.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Prolia.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Prolia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $122,757.05 | 48.3% | 135 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $116,066.58 | 45.6% | 217 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15,465.40 | 6.1% | 12 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $195,101.00 | 80 |
| Travel and Lodging | $52,205.14 | 195 |
| Food and Beverage | $6,974.93 | 88 |
| Education | $7.96 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $116,066.58 | 217 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $98,767.73 | 108 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $23,997.57 | 28 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15,465.40 | 12 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $72.38 | 4 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| PROLIA prolia |
2025 | Prolia | 2024 | 36 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
36 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 449 | 93 |
| Pantoprazole Sodium | Pantoprazole Sodium | 432 | 129 |
| Montelukast Sodium | Montelukast Sodium | 407 | 103 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 391 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 359 | 82 |
| Atorvastatin Calcium | Atorvastatin Calcium | 304 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 262 | 63 |
| Fluticasone Propionate | Fluticasone Propionate | 238 | 97 |
| Lisinopril | Lisinopril | 211 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 200 | 53 |
| Losartan Potassium | Losartan Potassium | 161 | 35 |
| Memantine Hcl | Memantine Hcl | 158 | 30 |
| Trazodone Hcl | Trazodone Hcl | 150 | 34 |
| Buspirone Hcl | Buspirone Hcl | 128 | 34 |
| Mirtazapine | Mirtazapine | 127 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 123 | 30 |
| Bupropion Xl | Bupropion Hcl | 121 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 116 | 25 |
| Potassium Chloride | Potassium Chloride | 115 | 33 |
| Metformin Hcl Er | Metformin Hcl | 114 | 27 |
| Prednisone | Prednisone | 107 | 79 |
| Xarelto | Rivaroxaban | 107 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 30 |
| Famotidine | Famotidine | 101 | 41 |
| Donepezil Hcl | Donepezil Hcl | 100 | 23 |
| Risedronate Sodium | Risedronate Sodium | 95 | 30 |
| Omeprazole | Omeprazole | 78 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 77 | 20 |
| Alprazolam | Alprazolam | 76 | 40 |
| Valsartan | Valsartan | 75 | 18 |
| Synthroid | Levothyroxine Sodium | 68 | 20 |
| Finasteride | Finasteride | 67 | 21 |
| Furosemide | Furosemide | 65 | 24 |
| Eliquis | Apixaban | 63 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 60 | 18 |
| Allopurinol | Allopurinol | 58 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 57 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 55 | 46 |
| Ibandronate Sodium | Ibandronate Sodium | 54 | 15 |
| Metformin Hcl | Metformin Hcl | 53 | 15 |
| Celecoxib | Celecoxib | 49 | 17 |
| Ipratropium Bromide | Ipratropium Bromide | 48 | 24 |
| Alendronate Sodium | Alendronate Sodium | 45 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 44 | 33 |
| Azithromycin | Azithromycin | 44 | 39 |
| Irbesartan | Irbesartan | 44 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 12 |
| Gabapentin | Gabapentin | 43 | 18 |
| Nebivolol Hcl | Nebivolol Hcl | 42 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | suppressed |
| Ramipril | Ramipril | 41 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 27 |
| Sertraline Hcl | Sertraline Hcl | 40 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | 18 |
| Januvia | Sitagliptin Phosphate | 39 | 12 |
| Naproxen | Naproxen | 39 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | 12 |
| Ezetimibe | Ezetimibe | 36 | suppressed |
| Prolia | Denosumab | 36 | 21 |
| Simvastatin | Simvastatin | 36 | 12 |
| Midodrine Hcl | Midodrine Hcl | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | 14 |
| Levofloxacin | Levofloxacin | 30 | 23 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Fluocinonide | Fluocinonide | 26 | suppressed |
| Carvedilol | Carvedilol | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Cephalexin | Cephalexin | 24 | 19 |
| Digoxin | Digoxin | 24 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 24 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 24 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Galantamine Er | Galantamine Hbr | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Rivastigmine | Rivastigmine | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 12 |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Dapsone | Dapsone | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Np Thyroid | Thyroid,pork | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Tymlos | Abaloparatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $254,289.03 · 364 records | GlaxoSmithKline, LLC. | AREXVY, CAPVAXIVE, EVENITY, PROLIA, SHINGRIX | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Prolia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error